The translocation t(12;22)(p13;q11) creates an MN1-TEL fusion gene leading to acute myeloid leukemia. MN1 is a transcription coactivator of the retinoic acid and vitamin D receptors, and TEL (ETV6) is a member of the E26-transformation-specific family of transcription factors. In MN1-TEL, the transactivating domains of MN1 are combined with the DNA-binding domain of TEL. We show that MN1-TEL inhibits retinoic acid receptor (RAR)-mediated transcription, counteracts coactivators such as p160 and p300, and acts as a dominant-negative mutant of MN1. Compared to MN1, the same transactivation domains in MN1-TEL are poorly stimulated by p160, p300 or histone deacetylase inhibitors, indicating that the block of RAR-mediated transcription by MN1-TEL is caused by dysfunctional transactivation domains rather than by recruitment of corepressors. The mechanism leading to myeloid leukemia in t(12;22) thus differs from the translocations that involve RAR itself.
Introduction
The translocation t(12;22)(p13;q11) leads to the formation of an MN1-TEL fusion gene in acute myeloid leukemia (AML) (Buijs et al., 1995) . The encoded fusion protein comprises nearly all of MN1 fused to the central part and DNA-binding domain of TEL. MN1, a protein of 1319 amino acids, is a transcription coactivator of the nuclear hormone receptors for all-trans retinoic acid (ATRA) and vitamin D (van Wely et al., 2003; Sutton et al., 2005) . Targeted disruption of the Mn1 gene causes a defect in the development of cranial membranous bones and death just after birth (Meester-Smoor et al., 2005) . The TEL gene, also termed ETV6, codes for a member of the E26-transformation-specific (ETS) family of transcription factors, and is the target of many different translocations leading to leukemia (Bohlander, 2005) . Whereas TEL confers its oligomerization domain in some translocations, it contributes the ETS-like DNA-binding domain in others, thus creating chimeric transcription factors with altered properties (Beverloo et al., 2001; Cazzaniga et al., 2001) .
The retinoic acid receptor (RAR) is a key regulator of proliferation and differentiation of blood cell lineages. RAR forms a dimer with RXR, and recruits p160 coactivators upon binding of ATRA to its ligandbinding domain (Leo and Chen, 2000) . In turn, the members of the p160 family bind other factors, for example, p300/CBP. This complex of coactivators contacts the basal transcription machinery and causes histone acetylation, which is thought to facilitate access of RNA polymerase (Goodman and Smolik, 2000) . In the absence of ATRA, RAR-RXR recruits corepressors like NCoR and SMRT, which in turn recruit histone deacetylase complexes containing SIN3 and HDAC (Heinzel et al., 1997) . Inhibition of RAR function, for example, by its fusion to promyelocytic leukemia (PML) protein, leads to downregulation of RAR-responsive genes, which results in a block in differentiation and an increase in the number of progenitor cells (Wang et al., 1998) . The transcription-repressing effect of PMLRARa relative to RARa is at least partially caused by a comparatively tight binding of corepressors (Guidez et al., 1998) . It is now widely believed that fusion transcription factors can cause leukemia by altering the balance between activation and inhibition of critical target genes.
The transforming activity of MN1-TEL in fibroblasts depends on the transactivation domains of MN1 and the DNA-binding domain of TEL (Buijs et al., 2000) , but the fusion protein also immortalizes myeloid cells and causes AML in mice (Kawagoe and Grosveld, 2005; Carella et al., 2006) . Although these studies have established the capacity of MN1-TEL to promote leukemia, they did not provide a molecular basis for its malignant effects. We therefore studied the fusion protein in a model system with established MN1 activity (van Wely et al., 2003) . MN1-TEL acts as an altered transcription factor compared to TEL, as it stimulates transcription from a reporter carrying responsive elements normally repressed by TEL (Buijs et al., 2000) . We now show that fusion to TEL also alters the properties of MN1. Rather than stimulating RARmediated transcription, as MN1 does, MN1-TEL inhibits RAR-mediated transcription. Moreover, MN1-TEL acts as a dominant-negative mutant, as it efficiently represses RAR-RXR-mediated transcription even in the presence of MN1. Thus, repression of RAR-responsive genes may be an important aspect of the leukemogenic activity of MN1-TEL.
Results

MN1-TEL does not synergize with RAR-RXR
Both MN1 and MN1-TEL stimulate transcription from the murine sarcoma virus long terminal repeat (MSV-LTR), and MN1 synergizes with RAR-RXR, p160 and p300 in the activation of this promoter (Buijs et al., 2000; van Wely et al., 2003) . The MSV-LTR comprises multiple transcription factor binding sites including a direct repeat 5 (DR5) ATRA-responsive element (van Wely et al., 2003) and several binding sites for ETS transcription factors (Gunther et al., 1990) . To determine whether MN1-TEL synergizes with RAR-RXR when stimulating the MSV promoter, we cotransfected human Hep3B cells with the MSV1 reporter and an MN1-TEL expression construct. Co-transfections were carried out either in the absence or presence of ATRA, thus activating the endogenous RAR-RXR (Wan et al., 1998) . MN1 and TEL cDNA expression constructs were used as controls, and expression was verified by Western blot analysis (Figure 1a and b) . MN1 stimulated transcription of the MSV-LTR and synergized with RAR-RXR after addition of ATRA (Figure 1c) . The transcriptional repressor TEL (Chakrabarti and Nucifora, 1999) inhibited transcription from the MSV-LTR (Figure 1d ). MN1-TEL also stimulated transcription, albeit less efficiently than MN1 (Figure 1e ). Addition of ATRA independently stimulated transcription, but the stimulation by ATRA was progressively lost in the presence of higher concentrations of MN1-TEL. Thus, in contrast to MN1, MN1-TEL does not synergize with RAR-RXR.
To analyse whether MN1-TEL exerts a similar effect on endogenous genes as it does on the MSV-LTR, we determined whether MN1 and MN1-TEL differentially regulate MEIS1 and S100A8 (MRP8), two RAR target genes involved in differentiation of hematopoietic cells (Van Roozendaal et al., 1990; Mercader et al., 2000; Hisa et al., 2004) . MEIS1 and S100A8 mRNA levels in U-937 cells expressing MN1 or MN1-TEL under the control of the tet-off system were determined by . The results were normalized using the mRNA levels of RNA polymerase 2 and presented relative to those in the presence of the tet-repressor. Compared to basal expression levels, both ATRA and MN1 individually induced MEIS1 and S100A8. MN1 expression in the presence of ATRA resulted in a synergistic induction. U-937 cells expressing MN1-TEL failed to induce MEIS1 and S100A8, and did not synergize with ATRA. MN1-TEL behaved similar to the control, showing a slight reduction of MEIS1 and S100A8 stimulation by ATRA upon tetracyclin release. The failure of MN1-TEL to synergize with RAR-RXR is thus a more general phenomenon and not restricted to the MSV-LTR.
MN1-TEL does not synergize with typical RAR-RXR coactivators
Stimulation of the MSV-LTR by MN1 is enhanced in a synergistic manner by p160 and p300, indicating that these coactivators mediate the synergy of MN1 and RAR-RXR (van Wely et al., 2003) . To determine whether MN1-TEL synergizes with p160 and p300, increasing amounts of RAC3 or p300 were co-transfected with either MN1 or MN1-TEL. MN1 stimulated transcription of the MSV-LTR, and a combination of MN1, ATRA and the p160 family member RAC3 markedly boosted the induction level ( Figure 3a ). An even stronger effect was observed when a combination of MN1, ATRA and p300 was used ( Figure 3b ). These effects were not recapitulated by a combination of MN1-TEL, ATRA and RAC3 (Figure 3c ) or p300 ( Figure 3d ), and MN1-TEL had a repressing effect on the final induction level in the presence of RAC3 or p300. These results demonstrated synergy when RAC3 or p300 and MN1 were transfected, but a clear absence thereof when combinations of RAC3 or p300 and MN1-TEL were used.
The activation domains in MN1-TEL do not function properly The MN1-TEL fusion protein contains nearly the complete MN1 sequence, including its transactivating domains that stimulate transcription through an interaction with p160 and p300 (van Wely et al., 2003) . Deletion of the MN1 transactivating domains from MN1-TEL abolishes activation of a TEL-responsive reporter (Buijs et al., 2000) . Given that MN1-TEL does not synergize with p160 and p300, its transactivating domains may not function properly. We thus examined the functionality of the transactivating domains in MN1-TEL with GAL4 DNA-binding domain (DBD) fusion constructs and a reporter containing GAL4 upstream activator sequences. The nuclear localization of fusion proteins was verified using antibodies to GAL4 (not shown), and Western blots of lysates of transfected cells showed similar expression of the fusion proteins ( Figure 4a ). Fusions of MN1 and the GAL4-DBD showed a strong transactivation of the reporter, when GAL4 was fused to the amino-(GAL4-MN1) or the carboxy-terminus (MN1-GAL4). The transcription activation by GAL4-MN1, and to a lesser extent MN1-GAL4, could be further stimulated by RAC3 (Figure 4b ) or p300 (Figure 4c ). The fusion of MN1-TEL and the GAL4-DBD, however, activated transcription far less efficiently than GAL4-MN1 and MN1-GAL4. Additionally, GAL4-MN1-TEL-driven transcription was stimulated ineffectively by RAC3 or p300. This indicates that, in contrast to MN1, MN1-TEL does not interact productively with p160 or p300. Given that TEL represses transcription by recruiting a histone deacetylase complex (Chakrabarti and Nucifora, 1999) , it is conceivable that these deacetylases counteract coactivators bound to MN1-TEL. To test this hypothesis, GAL4-MN1-TEL and the reporter were transfected in the absence or presence of trichostatin A (TSA), a potent inhibitor of histone deacetylases (Yoshida et al., 1990) . Addition of TSA further stimulated activation by GAL4-MN1, and to a lesser degree by MN1-GAL4 (Figure 4d ). Although GAL4-MN1-TEL was stimulated somewhat by TSA, its final activity was only one-fifth of that of GAL4-MN1, and was lower than that of MN1-GAL4. TSA concentrations above 0.6 mM did not result Figure 2 MN1-TEL MN1-TEL does not synergize with RAR-RXR-mediated induction of MEIS1 and S100A8. Expression of MN1 or MN1-TEL was induced by withdrawing tetracyclin (Àtet) from stably transfected U-937 cells in the absence or presence of ATRA. Subsequently, MEIS1 (a) and S100A8 (b) RNA levels were determined by quantitative RT-PCR. ATRA and MN1 each induce MEIS1 and S100A8, and together work synergistically. MN1-TEL, however, does not induce these RAR target genes and shows no synergy with ATRA.
MN1-TEL is a dominant-negative mutant KHM van Wely et al in further activation of the reporter. These results show that histone deacetylases may inhibit MN1-TEL to some extent, but its inability to transactivate efficiently is the major reason for its modest transcription activation.
The MN1 carboxy-terminus contributes to the transcription activity of the protein TEL fusion to the carboxy-terminus of MN1 eliminates its capacity to synergize with p160 and p300. Because GAL4 fusion to the MN1 carboxy-terminus also reduced the responsiveness towards coactivators, this may be a general phenomenon. To determine whether fusion of an unrelated protein domain could recapitulate this effect, we compared the transcription stimulation of the MSV-LTR by amino-terminal (GFP-MN1) and carboxy-terminal (MN1-GFP) fusions of green fluorescent protein (GFP) (Figure 5 ). GFP alone was transfected as control. Western blots of lysates of transfected cells revealed that the fusions were expressed at a similar level (Figure 5a ). Although both GFP-MN1 and MN1-GFP were able to stimulate MSV-LTR and synergized with RAR-RXR, the carboxy-terminal fusion was far less active than the amino-terminal fusion (Figure 5b) . Given that the carboxy-terminal fusion of GFP, GAL4 or TEL moieties all reduced MN1 performance, the carboxy-terminus contributes to its transcription activity. TEL fusion nonetheless appears to have a more severe effect than the fusion of GFP, as GAL4-MN1-TEL was less active than GAL4-MN1 and MN1-GAL4.
MN1-TEL has a dual effect on transcription and acts as a dominant-negative mutant of MN1 Mutation of the TEL DBD abolishes the ability of MN1-TEL to activate the MSV-LTR, showing that this domain enables MN1-TEL to activate transcription through TEL-responsive elements (Buijs et al., 2000) . On the other hand, MN1, RAR-RXR, p160 and p300 synergistically stimulate the MSV-LTR, whereas MN1-TEL does not. Therefore, the weak transactivation of the MSV-LTR by MN1-TEL compared to MN1 may be a combination of activation through TEL-responsive elements and repression through ATRA-responsive elements. To discriminate between these different modes of action, fully functional MN1-TEL was compared with a point mutant (MN1-TELDBDm) unable to bind TELresponsive elements (Buijs et al., 2000) . Whereas MN1-TEL may affect both TEL-and RAR-responsive elements, MN1-TELDBDm is predicted to act only on RAR-responsive elements. The MSV-LTR was stimulated strongly by MN1, moderately by MN1-TEL, but was repressed by MN1-TELDBDm (Figure 6a) . Hence, MN1-TEL has both a stimulatory and a repressing effect on transcription. TEL strongly repressed transcription. As the DBD mutant of TEL locates to the cytoplasm instead of the nucleus (Buijs et al., 2000) , it was not included in these experiments.
Several leukemia-associated fusion proteins affect the function of both partner proteins encoded by the remaining normal alleles (Beverloo et al., 2001; Cazzaniga et al., 2001) . To determine whether MN1-TEL interferes with MN1 function, a constant amount of MN1 construct was co-transfected with increasing amounts of MN1-TELDBDm, thus avoiding the stimulatory effect of Figure 4 The TADs in MN1-TEL do not respond to coactivators or histone deacetylase inhibitors. Expression constructs were transfected into Hep3B cells, and Western blot analysis using an antibody to MN1 showed comparable protein levels (a). Similar results were obtained using an antibody to GAL4 DBD (not shown). Luciferase reporters were co-transfected with fixed amounts of GAL4 fusion constructs and the indicated amounts of RAC3 or p300 constructs. GAL4-MN1 activates transcription in the presence of endogenous levels of coactivators. Whereas RAC3 (b) and p300 (c) synergistically enhance expression driven by GAL4-MN1 in a synergistic way (&), they stimulate MN1-GAL4 to a lesser degree (}) and do not productively stimulate GAL4-MN1-TEL (J) hybrid protein or GAL4 (n) control. Luciferase reporters were co-transfected with 125 ng GAL4 fusion constructs and treated with increasing concentrations of TSA (d). Addition of histone deacetylase inhibitors restored GAL4-MN1-TEL-(J) driven transcription only to levels well below those of GAL4-MN1 (&), and also below those of MN1-GAL4 (}). The GAL4 (n) control plasmid did not activate transcription. Figure 5 The MN1 carboxy-terminus contributes to its transcription-activating function. The MSV4 reporter was co-transfected with GFP alone or with GFP fused to the MN1 amino-(GFP-MN1) or carboxy-terminus (MN1-GFP). Fusion constructs were transfected into Hep3B cells, and Western blot analysis of cell lysates with a GFP antibody showed comparable protein levels. (a) Whereas GFP-MN1 efficiently stimulated transcription from the MSV-LTR, MN1-GFP was a markedly less potent activator (b). GFP alone (GFP-C3 and GFP-N3) did not stimulate transcription from the MSV-LTR.
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MN1-TEL on TEL-responsive elements. In the absence of MN1, MN1-TELDBDm caused a dose-dependent repression of reporter activity (Figure 6b ). MN1 and ATRA activated the MSV-LTR alone and in combination, but co-transfection of small amounts of MN1-TELDBDm efficiently repressed this activation. An equimolar ratio of MN1-TELDBDm and MN1 (125 ng), the situation that most likely mimics their expression in t(12;22)(p13;q11), activated the reporter only slightly above basal level and significantly diminished the stimulatory effect of ATRA. Higher amounts of MN1-TELDBDm did not further decrease activity. These results show that MN1-TELDBDm inhibits the normal activation of MSV-LTR by MN1 and RAR-RXR, and indicate that MN1-TEL acts as a dominant-negative inhibitor of MN1 on promoters without TEL-responsive elements.
Discussion
We have studied the properties of the MN1-TEL fusion protein, the product of t(12;22,p13;q11) associated with AML. This fusion protein was shown to activate TEL-responsive transcription, whereas TEL itself is a repressor (Buijs et al., 2000; Chakrabarti and Nucifora, 1999) . Now, we have compared the properties of MN1 and MN1-TEL with respect to RAR-RXR-mediated transcription, crucial for the proliferation and differentiation of blood cell lineages. Whereas MN1 functions as a coactivator for RAR-RXR, MN1-TEL inhibits RAR-RXR-mediated transcription. Furthermore, MN1-TEL seemed to act as a dominant-negative inhibitor of MN1, as it severely hampered the activation of RAR-RXR by MN1.
Using MN1-TELDBDm, a mutant that cannot bind DNA by itself, we have been able to distinguish between direct and indirect effects of MN1-TEL on promoters. MN1-TEL enhances transcription from TEL-responsive elements, by directly stimulating transcription, by competing with endogenous repressors such as TEL itself, or both. MN1-TEL may thus activate transcription of genes that are normally repressed by TEL. In our transfection experiments too, MN1-TEL stimulated transcription from the MSV-LTR. Unlike MN1 however, MN1-TEL neither synergized with RAR-RXR, p160 or p300, nor did it stimulate expression of the endogenous RAR-RXR target genes MEIS1 and S100A8. MN1-TELDBDm, which only affects RAR-RXR function, strongly repressed transcription. These results show that MN1-TEL has at least two distinct and opposing effects on MSV-LTR, a stimulatory activity dependent on direct recognition of responsive elements, and a repressive activity independent of direct DNA binding. MN1-TELDBDm not only repressed RAR-mediated transcription in the absence of MN1, but also diminished the stimulatory effect of ATRA when expressed at a concentration equimolar to that of MN1. This shows that MN1-TEL acts as a dominantnegative inhibitor of RAR and MN1 when eliminating the contribution of TEL-responsive elements.
ATRA did not prevent MN1-TEL from repressing RAR-RXR-mediated transcription. This suggests that MN1-TEL functions differently from the classical corepressor complexes containing NCoR and SMRT, which bind only in the absence of ATRA (Perissi et al., 1999) . In t(15;17) acute promyelocytic leukemia, the PML-RARa fusion protein binds corepressor complexes more tightly than RAR alone. Corepressor complexes can be released from PML-RARa with pharmacological doses of ATRA, or can be counteracted by histone deacetylase inhibitors in the case of the PLZF-RAR fusion (Guidez et al., 1998) . As TEL is a transcriptional repressor that recruits corepressors and histone deacetylases (Chakrabarti and Nucifora, 1999) , MN1-TEL could recruit such corepressor complexes to RAR-RXR. Nonetheless, even pharmacological doses of ATRA only marginally relieved the repression in our transfection assays, and experiments with histone deacetylase inhibitors showed that tight or irreversible binding of corepressor complexes is not the cause of MN1-TEL's inhibitory activity. Instead, MN1-TEL appears to block RAR-RXR-mediated transcription by preventing the productive recruitment of coactivator complexes. Accordingly, MN1-TEL inhibited the capacity of p160 and p300 to stimulate the MSV-LTR.
The fusion of N-terminal TADs to the DBD of ETS family members is not restricted to leukemias. The EWS-FLI fusion protein that causes Ewing sarcoma bears very similar characteristics (Bailly et al., 1994) . This fusion, too, may have both transcription-stimulating andrepressing effects (Braun et al., 1995) . Future studies may thus reveal the importance of the disruption of gene expression by this type of fusions in a wide variety of tumors. Whereas MN1-TEL was shown to activate TELresponsive elements (Buijs et al., 2000) , we now reveal that the fusion protein is also a dominant-negative suppressor of MN1 and RAR-RXR. ATRA or histone deacetylase inhibitors are unable to relieve this effect. Thus, a possible treatment of t(12;22) leukemia will likely require a novel combined strategy, aiming to reduce the stimulation of TEL-responsive promoters and simultaneously overcoming the inhibition of RAR-RXR.
Materials and methods
Plasmids and detection of fusion proteins
Dr A Zantema and Dr G Jenster provided expression constructs for p300 and RAC3, respectively. For expression purposes, MN1-TEL cDNA (Buijs et al., 1995) was cloned into vector pcDNA3 (Invitrogen, Carlsbad, CA, USA), resulting in plasmid pcDNA3MN1-TEL. An MN1 expression construct and reporter constructs bearing the MSV-LTR and GAL4 upstream activator sequences (van Wely et al., 2003) , and expression constructs for TEL and MN1-TELDBDm (Buijs et al., 1995) have been described. The pGL-MSV4 construct comprises a reporter containing the 360 base pair MSV-LTR excluding all sequences upstream of the first direct repeat. In pGL-MSV45, the 5 0 direct repeat of pGL-MSV4 has been replaced by the canonical DR5 sequence of the RARb promoter (Vivanco Ruiz et al., 1991) . Fusions to the GAL4 DNA-DBD were constructed in plasmid pGBT9 (Clontech, Palo Alto, CA, USA) and subsequently transferred to pcDNA3 for expression in mammalian cells. Fusions to GFP were made by cloning the MN1 cDNA sequence into pEGFP-C3 or pEGFP-N3 (Clontech) using internal BamHI or XhoI sites corresponding to MN1 amino acids 48 and 1292, respectively. Correct expression was confirmed by Western blotting. The antibody to MN1 (2F2) has been described (Buijs et al., 2000) . Antibodies to GAL4 (SC-510) and TEL (H-214) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and the antibody to GFP (no. 11814460) was from Roche, Basel, Switzerland.
Transient transfections
Hep3B cell were cultured in a-MEM supplemented with 5% fetal calf serum and antibiotics. For transient transfections, 8 Â 10 4 cells were seeded per well of a 24-well tissue culture plate. After 24 h, transfections were performed using 1.0 ml FuGENE 6 (Roche) per 0.5 mg of total plasmid DNA, as recommended by the manufacturer. Where indicated, ATRA (Sigma, St Louis, MO, USA) was added to a concentration of 1 mM and TSA (Sigma) to the specified concentration, both from ethanol stocks. Cells were harvested 24 h after transfection, lysed and luciferase expression was assayed on a Fluoroscan Ascent FL luminometer (Labsystems, Helsinki, Finland) . In all experiments, the total amount of transfected DNA and the molar ratio of cytomegalovirus promoter were kept constant. All transfections were performed at least three times and in triplicate, and the results proved highly reproducible. Protein expression by various fusion constructs was assayed by Western blotting of lysates of transfected cells, and their expression level was found to be similar, confirming that transfection efficiencies were reproducible within an experiment.
Inducible cell lines and real-time quantitative PCR U-937-derived (Gossen and Bujard, 1992 ) stable cell lines expressing MN1 or MN1-TEL under control of the tet-off system were generated essentially as described, by selecting cells transfected with pUHD10S plasmid bearing the cDNA of the gene of interest (Boer et al., 1998) . Empty vector was used as a control. U-937-derived cell lines were grown in RPMI 1640 supplemented with 10% fetal calf serum, antibiotics, 1 mg/ml tetracyclin, 0.5 mg/ml puromycin and 100 mg/ml hygromycin. Gene expression (3 Â 10 6 cells per sample) was induced by three washes in phosphate-buffered saline (PBS) and resuspension in 15 ml tetracyclin-free medium either without ATRA or containing 1 mM ATRA. Total RNA was extracted 24 h after induction with TRIzol reagent (Life Technologies, Gaithersburg, MD, USA) and further purified using RNeasy columns with on-column DNase treatment (Qiagen, Valencia, CA, USA). Total RNA (3 mg) was converted into cDNA with the M-MLV reverse transcriptase system (Invitrogen). Realtime qPCR was performed using the cDNA equivalent of 25 ng total RNA, 330 nM of each primer and 12.5 ml SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in a total volume of 25 ml. MEIS1 (ID3185) primer sequences were taken from the RTprimerDB (Pattyn et al., 2003) , POLR2A primers were provided by E Korpershoek and S100A8 primer sequences were 5 0 -ATG TTG ACC GAG CTG GAG AA-3 0 and 5 0 -CAG AAT GAG GAA CTC CTG GAA G-3 0 . Standards were prepared by fourfold serial dilutions of a pooled sample, consisting of equal amounts of cDNA from each of the MN1-and MN1-TEL-inducible cell lines. Quantitative RT-PCR was performed in duplicate for each biological duplicate, on an ABI 7700 (Applied Biosystems), annealing at 601C and measuring at 721C.
